Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinners after vein laser: which works best to stop dangerous clots?

NCT ID NCT07699796

Prevention Sponsor: Heart, Artery, and Vein Center of Fresno Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This trial tests whether a short 5-day course of the blood thinners rivaroxaban (Xarelto) or apixaban (Eliquis) can prevent blood clots that sometimes form after laser treatment for varicose veins. Adults with symptomatic vein reflux undergoing laser ablation of the great saphenous vein are randomly assigned to receive one of the two blood thinners or no blood thinner. The study tracks clot formation using ultrasound to see which approach is safest and most effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rivaroxaban (Xarelto) and apixaban (Eliquis)
What this could lead to
If one blood thinner works better, it could become the standard short course to prevent clots after this common vein procedure.
What could go wrong
This is a single-centre trial, so results may not apply everywhere. Blood thinners also carry a small risk of bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

564 people

The number who actually took part.

Started

Mar 2018

Finished

Jun 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults aged 18 years or older Undergoing great saphenous vein endovenous laser ablation for symptomatic reflux Concurrent below-knee foam sclerotherapy Exclusion Criteria: Known thrombophilia Current oestrogen or hormone-replacement therapy Family history of venous thromboembolism or thrombophilia Active malignancy Prior ipsilateral ablation Deep venous reflux or obstruction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic venous insufficiency are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic venous insufficiency thrombophilia due to thrombin defect varicose disease venous insufficiency Venous Thrombosis thrombotic disease prevention target venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Varicose veins leg Venous insufficiency (chronic)(peripheral) Venous thrombosis Venous thrombosis deep (limbs)

Contacts and locations

Locations

  • Heart Artery and Vein Center of Fresno

    Fresno, California, 93722, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.